During the past decade, Birmingham Psychiatry Pharmaceutical conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Birmingham Psychiatry Pharmaceutical" are "Schizophrenia" (4 trials), "Major Depressive Disorder" (2 trials), "Depressive Disorder, Major" (1 trials) and "Depressive Disorder, Treatment-Resistant" (1 trials). Many other conditions were trialed in "Birmingham Psychiatry Pharmaceutical" in a lesser frequency.

Most popular intervention types in "Birmingham Psychiatry Pharmaceutical" are "Drug" (8 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Lurasidone 20 mg" (2 trials), "DVS SR" (1 trials), "Desvenlafaxine Succinate Sustained-Release" (1 trials) and "Esketamine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Birmingham Psychiatry Pharmaceutical" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Birmingham Psychiatry Pharmaceutical". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Birmingham Psychiatry Pharmaceutical, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Birmingham Psychiatry Pharmaceutical, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".